Evidence map›Paper›PMID 42050932›Full record

ArticleHGG advances2026

Diagnostic utility of clinical genome reanalysis in rare pediatric disorders using long-read sequencing.

Elizabeth A Werren, Purva Vats, Gabriel E Rech, Michael Peracchio, Cameron King, Elizabeth J Charnysh, Ryan D Gorham, Peter A Audano, Peter N Robinson, Melissa A Kelly and 3 more

Abstract read
In one paragraph

Article in HGG advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Elizabeth A WerrenThe Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
Purva VatsThe Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
Gabriel E RechThe Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
Michael PeracchioDivision of Genetics, Connecticut Children's, Hartford, CT 06106, USA.
Cameron KingDepartment of Research, Connecticut Children's, Hartford, CT 06106, USA.
Elizabeth J CharnyshThe Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
Ryan D GorhamThe Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
Peter A AudanoThe Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
Peter N RobinsonThe Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
Melissa A KellyThe Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
Adam P MatsonDepartment of Pediatrics, University of Connecticut School of Medicine, Farmington, CT 06030, USA; Division of Neonatology, Connecticut Children's, Hartford, CT 06106, USA; Department of Immunology, UConn Health, Farmington, CT 06030, USA.
Mark D AdamsThe Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA. Electronic address: mark.adams@jax.org.
Louisa KalsnerDivision of Genetics, Connecticut Children's, Hartford, CT 06106, USA; Department of Pediatrics, University of Connecticut School of Medicine, Farmington, CT 06030, USA; Division of Neurology, Connecticut Children's, Hartford, CT 06106, USA. Electronic address: lkalsner@connecticutchildrens.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over half of presumed genetic disease cases remain undiagnosed following short-read exome sequencing (SR-ES) or genome sequencing (SR-GS). Long-read GS (LR-GS) shows promise for uncovering etiologies missed by SR genetic testing, particularly structural variants (SVs). However, SV interpretation remains challenging due to limitations in call reliability, population allele frequency estimates, and functional impact prediction. To advance clinical LR-GS implementation, we analyzed the genomes of 19 children with suspected rare genetic conditions and prior negative or inconclusive clinical SR-GS/SR-ES as well as their parents using PacBio HiFi LR-GS. One additional family with limited DNA underwent Illumina SR-GS only, and 11 probands received SR-GS to complement small-variant detection. LR-GS data were processed using phased-assembly and read-based variant-calling pipelines validated in SV-positive control subjects, while SR-GS data were processed with the Illumina DRAGEN pipeline. Variants were prioritized using phenotype-driven approaches. Diagnostic variants (likely pathogenic or pathogenic) were identified in 2/20 (10%) families, while an additional 5/20 (25%) harbored findings of uncertain diagnostic significance, including variants of uncertain significance (VUSs) and variants in genes of uncertain significance (GUSs). All reported variants were detected independently of LR-GS by research SR-GS or by reanalysis of prior clinical SR data. Several LR-GS SV candidates were excluded after population allele frequency filtering, underscoring its importance in clinical SV interpretation. Overall, the observed 10% increase in diagnostic yield was achievable through SR analysis alone, as LR-GS was not required to identify diagnostic variants in this cohort. Functional studies are needed to clarify the clinical relevance of uncertain findings.

Indexed as

Genetic TestingGenome, HumanRare DiseasesChildChild, PreschoolExome SequencingFemaleGene FrequencyHigh-Throughput Nucleotide SequencingHumansMaleSequence Analysis, DNAclinical variant interpretationlong-read genome sequencingrare disease

Identifiers

PMID42050932
PMCPMC13202554

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.